ZEPOSIA DIN 02506009
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Molecule: OZANIMOD (OZANIMOD HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | OZANIMOD (OZANIMOD HYDROCHLORIDE) 0.23 MG; OZANIMOD (OZANIMOD HYDROCHLORIDE) 0.46 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L04AE02 OZANIMOD |
| Original market date | 12-Nov-2020 |
| Current status date | 14-Feb-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OZANIMOD (OZANIMOD HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02505991 | ZEPOSIA | BRISTOL-MYERS SQUIBB CANADA | Capsule | OZANIMOD (OZANIMOD HYDROCHLORIDE) 0.92 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32330 | 2023-12-08 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 24355 | 2020-10-02 | New Drug Submission (NDS) |